ASKC202 clinical trials
ASKC202 is named as an intervention in 3 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Jiangsu Aosaikang Pharmaceutical Co., Ltd. The most-studied condition is EGFR Activating Mutation.
Patient leaflets for ASKC202
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of ASKC202
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
NCT07109531 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic NSCLC
|
Phase 3 | Recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd | China |
|
Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067
NCT05306132 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1 | Recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd | China |
|
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT07897188 · ClinicalTrials.gov ↗ · EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive
|
Phase 3 | Not yet open | Jiangsu Aosaikang Pharmaceutical Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with ASKC202
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Jiangsu Aosaikang Pharmaceutical Co., Ltd | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 2 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about ASKC202 trials
How many clinical trials are testing ASKC202?
3 current trials in our China register name ASKC202 as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are ASKC202 trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors ASKC202 clinical trials?
The lead sponsor is Jiangsu Aosaikang Pharmaceutical Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ASKC202 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ASKC202 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ASKC202 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.